Evidence map›Paper›PMID 39907698›Full record

ArticleACS chemical neuroscience2025

Therapeutic Potential of Arimoclomol Nanomicelles: In Vitro Impact on Alzheimer's and Parkinson's Pathology and Correlation with In Vivo Inflammatory Response.

Isabelle Xavier-de-Britto, Natália Cristina Gomes-da-Silva, Marilia Amável Gomes Soares, Cristian Follmer, David Dabkiewicz, Luciana Magalhães Rebelo Alencar, Celso Sant'Anna, Tatiana Paula Teixeira Ferreira, Patrícia Machado Rodrigues E Silva Martins, Eduardo Ricci-Junior and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Isabelle Xavier-de-BrittoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, Rio de Janeiro 21941906, Brazil.
Natália Cristina Gomes-da-SilvaBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, Rio de Janeiro 21941906, Brazil.ORCID 0000-0002-9088-6671
Marilia Amável Gomes SoaresBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, Rio de Janeiro 21941906, Brazil.
Cristian FollmerLaboratory of Biological Chemistry of Neurodegenerative Disorders, Department of Physical Chemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, Brazil.
David DabkiewiczLaboratory of Biological Chemistry of Neurodegenerative Disorders, Department of Physical Chemistry, Institute of Chemistry, Federal University of Rio de Janeiro, Rio de Janeiro 21941-909, Brazil.
Luciana Magalhães Rebelo AlencarBiophysics and Nanosystems Laboratory, Federal University of Maranhão, Department of Physics, São Luis, Maranhão 65065690, Brazil.ORCID 0000-0001-8210-2016
Celso Sant'AnnaLaboratory of Microscopy Applied to Life Science-Lamav, National Institute of Metrology, Quality and Technology, Duque de Caxias, Rio de Janeiro 25250-020, Brazil.
Tatiana Paula Teixeira FerreiraLaboratory of Inflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil.
Patrícia Machado Rodrigues E Silva MartinsLaboratory of Inflammation, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil.
Eduardo Ricci-JuniorFederal University of Rio de Janeiro, School of Pharmacy, Rio de Janeiro, Rio de Janeiro 21941900, Brazil.
Pierre Basílio Almeida FechineGroup of Chemistry of Advanced Materials (GQMat)-Department of Analytical Chemistry and Physical-Chemistry, Federal University of Ceará, Fortaleza, Ceará 451-970, Brazil.ORCID 0000-0002-7822-2354
Ralph Santos-OliveiraBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro, Rio de Janeiro 21941906, Brazil.ORCID 0000-0002-0905-481X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the potential of arimoclomol-loaded nanomicelles for the treatment of neurodegenerative diseases like Alzheimer's and Parkinson's, as well as their anti-inflammatory properties. Arimoclomol, a coinducer of heat shock proteins (HSPs), has shown clinical promise in mitigating protein misfolding, a hallmark of these diseases. In this work, arimoclomol nanomicelles significantly reduced the aggregation of β-amyloid (Aβ

Indexed as

Alzheimer DiseaseAnti-Inflammatory AgentsInflammationParkinson Diseasealpha-SynucleinAmyloid beta-PeptidesAnimalsHumansMaleMiceMicellesNanoparticlesPeptide Fragmentsalpha-SynucleinAmyloid beta-Peptidesamyloid beta-protein (1-42)Anti-Inflammatory AgentsMicellesPeptide Fragmentsdrug deliveryinflammationneurodegenerative disease

Identifiers

PMID39907698
PMCPMC11843614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.